lijun
Lv1
40 积分
2022-12-29 加入
-
VTE risk profiles and prophylaxis in medical and surgical inpatients: the identification of Chinese hospitalized patients′ risk profile for venous thromboembolism (DissolVE‑2)‑a cross‑sectional study
10天前
已完结
-
Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial
1个月前
已关闭
-
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
1个月前
已完结
-
[Guideline for HER2 detection in breast cancer, the 2019 version]
3个月前
已完结
-
[Consensus on the application of immunohistochemistry in breast pathology (2022 version)]
3个月前
已完结
-
RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies
3个月前
已关闭
-
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
3个月前
已完结
-
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
3个月前
已完结
-
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto
3个月前
已完结
-
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
5个月前
已完结